Purpose/Objective: To evaluate through Doppler ultrasound the intratumoral vascularization of uveal melanoma (UM) at diagnosis as a sign of tumoral activity, and to quantify its presence after treatment with brachytherapy. Materials and Methods: 50 cases of UM were treated with brachytherapy from July 2005 to June2010. 26 men and 24 women with an average age of 60. 70% melanotic, 18% amelanotic and 12% mixed. Location: 30% posterior, 16% postequatorial, 22% equatorial, 20%peripheral and 12% in ciliary body. Mean basal size and apical thickness at diagnosis: 12.1 x 5.6 mm (SD 3.0-5.6). A 125-Iodine plaque was used in 70% of cases and 106-Ruthenium in 28%. Transpupillary thermotherapy (TTT) was associated in 10 cases. The apical dose was 85 Gy. Mean follow-up was of 29 months (13.7-69 months). Duplex Doppler scans (gray scale and Doppler scans) were done at diagnosis and every 6months after treatment. Parameters evaluated: presence of intratumoral vessels, systolic peak velocity (SPV), end-diastolic velocity (EDV) and resistance index (RI= systdiast/syst). Results: Doppler detected intratumoral vascularization at diagnosis in 21 of 50 cases (42%): vascularization persisted in 7 cases at 6, 12 and 18 months. At 24 months only persisted 5/31, at 30 months 3/20, at 36 months 1/12, at 42 months 1/6, at 48 months 1/3, at 54 months 1/2 and at 60 months 0/1. Mean systolic peak velocity at diagnosis was 25.2±16.1 cm/s and 15.82±10.5 at 6 months. The treatment had asignificant impact on the detection of tumour vessels (p=0.035), controlled by age, sex, maximum tumoral diameter and tumoral thickness in a logistic regression model. Mean resistance index (RI) was lower in tumours before treatment (0.50 vs 0.59, p=0.0047). Out of 6 tumours with persistent signal during follow-up, 4 were in regression, 1 large tumour recurred and was enucleated, and another large one developed metastases. 8 avascular tumors at diagnosis experienced new vascularization during follow-up: 1 recurred and was enucleated and the other 7 showed ophthalmoscopic and echographic regression, and vascularization eventually disappeared. 4 of them developed neovascular glaucoma (NVG). Reduction of the apical thickness was more significant in initially vascularized tumors that had lost the Doppler signal than in tumors that remained avascular or vascular at 6months (p=0.365). The SPV dropped significantly at 6 months (p=0,028) but EDVdid not (p=0.116).
Purpose/Objective: Hilar cholangiocarcinoma (Klatskin tumours) are rare tumours with poor prognosis. The purpose of this work was to determine efficacy, toxicity, and patterns of recurrence in patients treated with endobiliary radiotherapy (RT) and external beam RT (EBRT) with chemotherapy. Materials and Methods: From Aug 2005 to July 2012, 65 patients with locally advanced non-metastatic hilar cholangiocarcinoma and were studied. All the patients presented with jaundice and required percutaneous biliary drainage. Endobiliary RT using HDR -Iridium 192 (median dose 14 Gy/4# b.i.d), was delivered through the PTBD catheter which was followed by metal stenting. Twenty two (34%) patients received only endobiliary RT, while 27 (41%) patients after brachytherapy were further treated with concurr (median dose 45Gy/25#). Sixteen (25%) patients in who were referred after metal stenting received Intensity modulated radiotherapy to a dose of 57Gy/25# with concurrent Inj. Gemcitabine (300mg/mt2 weekly). Histopathological diagnosis was available in 50 patients (77%). Results: Median follow up for whole group was 7 months (range 1-31 months). Twelve patients had complete response, 30 patients had partial response and 12 patients had stable disease, while 11 patients had locally progressive disease after radiation. Twenty one patients were alive at last follow up. The median overall survival (OAS) was 7 months and one year OAS and Cancer specific survival (CSS) was 44% and 51% for whole group. Patients receiving endobiliary combined with chemoradiation or high dose chemoradiation alone had better survival as compared to patients receiving only endobiliary RT at 1 year (55% vs.17%, p=0.001). The main sites of distant disease progression were liver and peritoneum. Thirty one patients (48%) developed cholangitis of which 8 patients succumbed to it. Four patients had late radiation toxicity, of these 3 had hematemesis due to duodenitis and one had radiation induced stricture at gastroesophageal junction requiring dilatation. Conclusions: These encouraging results suggest that endobiliary radiation in addition to chemoradiation is feasible with acceptable toxicity in unresectable Klatskin tumors and leads to better outcome as compared to those receiving only endobiliary RT alone.
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Surgical resection followed by HDR brachytherapy for management of keloids at high risk for recurrence J. Glanzman 1 , P. Weiss 2 , K. Mehta 1 , W. Bodner 1 , S. Kalnicki 1 , M. Garg 1 1 Montefiore Medical Center, Radiation Oncology, Bronx NY, USA 2 Montefiore Medical Center, Plastic Surgery, Bronx NY, USA Purpose/Objective: Keloids are challenging lesions to treat with high rates of recurrence. There are a multitude of treatment options available with various rates of success. Evidence has shown surgical resection followed by RT to have the highest level of local control and numerous reports have shown control rates of 65 -90% with adjuvant external beam RT. Prior studies have demonstrated a spectrum of aggressiveness for keloids. Secondary keloids or lesions that have undergone prior resection and then recurred are often refractory to further treatment with higher rates of recurrence. Keloids that recur after combined surgery and EBRT are especially difficult cases and limited in therapy options. The objective of our study was to determine the efficacy of surgical resection of keloids followed by HDR brachytherapy for management of lesions at high risk for recurrence.
Materials and Methods:
This study is a retrospective analysis of 18 patients representing 29 keloids found on various body sites including the chest wall, axilla, breast, ear, pelvis, chin, cheek, neck, back, shoulder, and abdomen, treated at Montefiore Medical Center between 1996 and 2011. Our study population consisted of mainly secondary lesions already treated in the past with the combination of surgery and EBRT, lesions treated with surgery alone, or primary keloids deemed to be at a high risk for recurrence due to their size and location. The treatment in this study consisted of complete surgical excision with placement of hollow brachytherapy catheters, immediately followed by HDR Iridium-192 brachytherapy to a total dose of 15Gy in 3 fractions, over 3 consecutive days, prescribed to a 1cm depth. Endpoints assessed included recurrence rate, treatment complications, and side effects. 14 lesions had undergone prior resection(s) and external beam radiation, 6 had previously received surgery alone, and 9 were primary lesions. The two most common sites were earlobe and chest wall. The mean age at treatment was 43 (range 23-64 years). Results: The mean follow up in our study was 62 months (range 12-192 months). Analysis of the data demonstrated a recurrence-free rate of 89.6% (26/29 lesions). Two of the recurrences had received previous surgery and EBRT and one was a primary keloid with no prior treatment. 7 patients experienced delayed wound healing but eventually had a full recovery. 3 patients had post-operative infections at the surgical site that were successfully treated. Two patients experienced mild intermittent parasthesias at the treatment site and one complained of mild pruritis post-treatment. For the other 26 lesions, there was an improvement in keloid symptoms including pain, parasthesias, and pruritis. Conclusions: Surgical resection and adjuvant HDR Iridium-192 brachytherapy provide excellent and enduring levels of local control for keloid lesions at high risk for recurrence and are well tolerated with acceptably minimal long term side effects with a mean follow up of 62 months. interstitial brachytherapy (BRT) in the anal canal based on RM guidance. Materials and Methods: After a month from the end of the combined treatment RTCT, all the patients got a clinical examination, a PET-CT and a MRI. The prescribed brachytherapy target volume (TV) was individuated, supported by a radiologist, by MRI performed with vaginal applicator (MRI compatible) positioned in the anus. With a MUPIT applicator (Elekta©) in situ a CT simulation was performed. CT images were fused with MRI by deformable co-registration (Velocity©). A treatment pre-plan was created in order to have information on the optimal position of the needles. Then the needles were positioned according to the indications of the pre-treatment plan. Afterward the patient underwent again a CT scan and the definitive treatment plan was created on Oncentra Brachy© console. Results: From February to June 2012, we treated 4 patients. 3 patients had histological diagnosis of squamous cell anal canal carcinoma (SCACC), instead 1 patient was a low rectum adenocarcinoma. The median age was 61,5 (range 49-78). There were: 2 patients cT2N0M0, 1 patient cT4N0M0 and1 patient cT4N2M0. A patient didn't ultimate the RT-CT combined treatment for toxicity. No complications were observed during and after the implant. The early follow up indicates no episodes of common complications at the first follow-up. Three patients had a complete response without tumor evidence and were alive without local recurrence or metastases. The patient that didn't ultimate RT-CT treatment had a local persistance. The dosimetric analysis showed that the mean TV was 16,03 cc and the mean TV covered by almost 100% of dose was 14.73 cc. The mean percentage of TV covered by less than 100% of dose was 4,9%.
PO-0987 MRI-Adaptive image guided brachytherapy (AIBT) in anal canal

Conclusions:
The integration of MRI guidance in BRT procedures seems to offer a better evaluation of the pelvis district adapting plan of treatment at the TV. Patients had a good compliance and no episodes of complication for now. To evaluate the clinical results in terms of local control and survival we need a longer follow up and a more representative sample. Purpose/Objective: The first treatments with INTRABEAM ® system (Carl Zeiss SAS) using low energy X-rays were performed in our institution in October 2011. Between 2004 and 2011 an electron linear accelerator was used for intraoperative irradiation of the breast for 82 patients. Materials and Methods: Fifty-nine patients of mean age 71 years have now been treated with INTRABEAM ®. For each, the radiation dose required was 20 Gy to the surface of the surgical margin in a single fraction. With the linear accelerator, 21 Gy were prescribed to the 90% depth dose of the chosen energy. The system INTRABEAM ® produces low energy photons from a 50 kV and 40μA source while preceding irradiation technique used electrons energy of 6 or 9 MeV. The isotropy of the low energy photon beam and the dose rate were measured before each treatment with a specific system and a calibrated ionization chamber. During irradiation with electrons, we realized an 'in vivo' measurement with a semiconductor placed at the tumor bed by the surgeon and the radiotherapist during the positioning of the applicator. With the new technique, sterile applicators with variable diameters from 3 to 5 cm are selected to exactly fit the surgical cavity, thus allowing a homogeneous spherical irradiation. In our previous technique, the tumor bed 'flattened' was systematically located 2 cm from the edge of the applicator (4 to 6 cm in diameter) to get a sufficient safety margin for processing. Results: With INTRABEAM ®, the dose attenuation is rapid (5.4 Gy at 1 cm from the applicator surface), thereby reducing damage to surrounding healthy tissue. For treatment, mobile system is installed in one of two operating ambulatory surgery designed in accordance with radiation protection standards and does not require as before the immobilization of a radiotherapy bunker. The average time needed to deliver the dose was 27 minutes for 59 patients using the low energy photon technique. This time depends on the size of the applicator and is longer than the 11 minutes used before to deliver the prescribed dose with electrons. However, the total time needed for the room and the staff is not more important with INTRABEAM ® system as before.
POSTER: IORT: BREAST CANCER
PO-0988 Comparison between linear accelerator and INTRABEAM® system for intraoperative radiotherapy of the breast.
Conclusions:
The shift from breast intraoperative radiotherapy using a linear accelerator to INTRABEAM® was realized with no major problems in our institution. Using this new system has improved the workflow of radiotherapy and surgery, and thus increases the number of patients that can benefit from this technique. Purpose/Objective: In the last ten years, intraoperative radiotherapy has been used extensively in the clinical setting as the exclusive mode of partial breast irradiation or as tumor bed boost during BCS. A careful diagnostic evaluation is essential for the choice of the most appropriate treatment. Most international guidelines recommend a multidisciplinary approach for patients with breast cancer. The multidisciplinary team provide to establish quality standards in the multiple aspects of the treatment and may be particularly important for a procedure as IORT in which different professionals must work together for the successful implementation of the treatment. Materials and Methods: In our center, since February 2005 we treated about 500 cases of breast cancer with IORT and since January 2011, all patients were evaluated by the multidisciplinary team made up of surgeon, radiologist, radiation oncologist, medical oncologist, pathologist, radiographers and nurses. The selection of patients to be able to be submitted to IORT exclusively takes place, in agreement with the surgeon, on the basis of the ASTRO guidelines, all other patients are treated with EBRT and intraoperative boost. One of the main limitations in the use of IORT is the absence of pathology information; in our center all patients received core-biopsy with the evaluation of predictive parameters (histology, grading, Her2, ER, PgR, Ki67). During the surgery extemporaneous histological examination is performed to evaluate the surgical margins and the sentinel lymph node. Results: Since January 2011 to October 2012 in our hospital 152 patients were treated with BCS and IORT. All patients were evaluated by the multidisciplinary team before and after surgery. 37 patients, had a biopsy compliant with the ASTRO criteria and received IORT exclusively, 115 received anticipated boost. Histologically, three patients treated with IORT exclusive, were not fully compliant with the ASTRO criteria: in one case there was evidence of neoplastic thrombus in the sentinel node, in the other case the grading was 3 and in the last case it was a lobular form. Conclusions: An integrated, multidisciplinary approach is desiderable to treat all patients. We consider IORT a safe procedure, with good cosmetic results, allowing more women to have access to breast conserving therapy; a careful selection of patients who may benefit from a partial breast irradiation is needed. We believe that the corebiopsy examination can be very predictive and therefore mandatory before an exclusive treatment.The close and constant collaboration with the surgeon and the pathologist has been essential in the improvement of the entire procedure.
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Software for calculating the dose distribution in the low-energy X depending on the angle of incidence S. Marcié 1 , O. Croce 2 , S. Hachem 2 , J.P. Gérard 3
